Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001449 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00001449: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001449 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001449, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the clinical toxicities associated with administering sequential dFdC as a one hour infusion followed by a continuous infusion of FUdR over 24 hours with low dose oral LV weekly for three weeks out of four.
Interventions
- DRUG gemcitabine
- DRUG leucovorin
- DRUG fluorodeoxyuridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1995-09 |
| Est. Completion | 2000-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001449
The ClinicalTrials.gov registry entry for NCT00001449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which gemcitabine is the first listed.
NCT00001449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001449 about?
NCT00001449 is a clinical study titled "A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients". The purpose of this study is to determine the clinical toxicities associated with administering sequential dFdC as a one hour infusion followed by a continuous infusion of FUdR over 24 hours with low dose oral LV weekly for three weeks out of four.
What is the current status of trial NCT00001449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 1995-09. Estimated completion is 2000-04.
What interventions are being tested in trial NCT00001449?
The interventions under investigation include: gemcitabine (DRUG), leucovorin (DRUG), fluorodeoxyuridine (DRUG).
Who is sponsoring clinical trial NCT00001449?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.